Researchers at the Max Delbrück Center led by Altuna Akalin have developed Flexynesis, an advanced deep learning framework designed to integrate complex multi-omics datasets with clinical information. Published in Nature Communications, Flexynesis empowers precision cancer therapy by enabling comprehensive data analysis to identify patient-specific biomarkers and therapeutic targets. This innovation exemplifies the growing role of artificial intelligence in tailoring oncological treatments and accelerating personalized medicine.